: Fluorescence images of cells associated with experiments described in Figure 3A . Each aaRS is cotransfected with three different nonsense suppressors of its cognate tRNA and the appropriate EGFP-mutant to evaluate how well each pair suppresses the three different nonsense codons.
Figure S2:
Fluorescence images of cells associated with experiments described in Figure 3B . Each of the three nonsense suppressing mutants of tRNA Pyl is co-transfected with three different nonsense mutants of EGFP, as well as PylRS, to evaluate if any of the nonsense suppressors can charge a non-cognate nonsense codon.
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Figure S3: Fluorescence images of cells associated with the following experiments related to those described in Figure 3B . Each of the three nonsense suppressing mutants of tRNA EcTyr is cotransfected with three different nonsense mutants of EGFP, as well as EcTyrRS, to evaluate if any of the nonsense suppressors can charge a non-cognate nonsense codon. Figure 3C . Each of the three different aaRSs was cotransfected with the three different TAG-suppressing tRNAs, as well as EGFP-39-TAG, to identify potential aminoacylation of non-cognate tRNAs.
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Figure S5:
Maps for different plasmids constructed to facilitate site-specific dual ncAA incorporation.
Figure S6: Site-specific incorporation of different combinations of two distinct ncAAs into EGFP-39-TAG-151-TGA. For each ncAA combination, efficiency of full-length EGFP expression is reported, measured by its characteristic fluorescence in cell-free extract, upon transfecting HEK293T cells with pAcBac3-EcTyr TGA -EGFP** and pAcBac1-Pyl TAG , or pAcBac3-EcTyr TGA -EGFP** and pAcBac1-Pyl TAG . While the former suppression systems provides higher dual ncAA incorporation yields in general, the latter system was better when incorporating AzK+PrY. Figure 6A . Sitespecific incorporation of two different bioconjugation handles into EGFP-39-TAG-151-TGA. A) Upon transfecting HEK293T cells with pAcBac3-EcTyr TGA -EGFP** and pAcBac1-Pyl TAG (for hPrK+AzF, AzK+AcF, and CpK+AzF), or pAcBac3-EcTyr TAG -EGFP** and pAcBac1-Pyl TGA (for AzK+PrY). A representative image of cells in the absence of the ncAAs was also included.
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Figure S9: ESI-MS analysis of purified EGFP-39-TAG-151-TGA reporter incorporating indicated ncAAs. Lower panels show raw data, upper panel the deconvoluted mass. In all cases, the observed mass confirms incorporation of the desired ncAAs into indicated sites.
EGFP-39hPrK-151AzF
EGFP-39PrY-151AzK
EGFP-39AzK-151AcF
Figure S10: A) Structures of DBCO-Cy5 and AF488-PCA. Treating EGFP-39hPrK-151AzF (B) and EGFP-39PrY-151AzK (C) with DBCO-Cy5 or AF488-PCA (Cu(I)-catalyzed) leads to appropriate fluorescence-labeling, corroborating the presence of the alkyne and azide functionalities. Wild-type EGFP fails to undergo labeling under identical conditions.
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Materials and Methods
General materials:
Oligonucleotides and gBlock gene fragments were obtained from IDT. Phusion Hot Start II DNA polymerase, restriction enzymes and T4 DNA ligase were purchased from Fisher Scientific. Various antibiotics were supplemented in media (bacterial culture) at following concentrations: 100 μg/mL ampicillin, 10 μg/mL gentamycin, 50 μg/mL kanamycin. TOP10 E. coli cells are used for cloning and plasmid propagation. For mammalian cell culture, Dulbecco's modified Eagle's medium (high glucose DMEM), trypsin 0.25% (1X) solution, PenicillinStreptomycin (10,000 U/mL) and fetal bovine serum (FBS) were obtained from Fisher Scientific. For transient transfection, we used polyethylenimine (PEI MAX 40000) from Polysciences (Warrington, PA). For protein purification, TALON His-tag purification resin is obtained from Takara (Clontech). DNA sequencing was performed by Eton Biosciences.
Construction of plasmids to express aaRS, tRNA or EGFP* individually:
The previously reported pAcBac1, pAcBac2 and pAcBac3 vectors were used to generate additional plasmids. 1 To make a plasmid that only expresses M. bakeri pyrrolysyl synthetase (MbPylRS), DNA sequence encoding for MbPylRS was PCR amplified, digested with NheI/EcoRI and inserted into pAcBac1 vector. The same strategy was also used to generate a pAcBac1 plasmid that expresses E. coli leucyl synthetase (EcLeuRS-AK1). 2 Standard site-directed mutagenesis was used on pAcBac1-EGFP-39TAG 1 to create variants that encode EGFP-39TAA or EGFP-39TGA.
DNA sequence encoding one copy of E. coli tyrrosyl tRNA CUA (tRNA CUA EcTyr ) driven by U6 promoter was PCR amplified from pIDT-Kan-2xtRY 1 , and inserted into pIDT-Kan vector between NheI and AvrII to generate pIDT-Kan-1xU6tRNA CUA EcTyr . Using site-directed mutagenesis of this plasmid, pIDT-Kan-1xU6tRNA UCA EcTyr and pIDT-Kan-1xU6tRNA UUA EcTyr were generated, which encodes the TGA-or TAA-suppressing E. coli tyrosyl tRNA, respectively. DNA sequences encoding M. mazei pyrrolysyl tRNA CUA (tRNA CUA Pyl ) and E. coli leucyl tRNA CUA (tRNA CUA EcLeu ) were synthesized by IDT. gBlock fragments encoding these sequences were PCR amplified, digested with NheI/AvrII and insert into pIDT-Kan vector to generate pIDT-Kan1xU6tRNA CUA Pyl and pIDT-Kan-1xU6tRNA CUA EcLeu . Site-directed mutagenesis was later performed to generate plasmids harboring the corresponding anticodon variants: pIDT-Kan1xU6tRNA UCA Pyl , pIDT-Kan-1xU6tRNA UUA Pyl , pIDT-Kan-1xU6tRNA UCA EcLeu , and pIDT-Kan1xU6tRNA UUA EcLeu .
Construction of plasmids for incorporating two ncAAs into EGFP:
To generate plasmids that allow the expression of five essential components (two mutually orthogonal aaRS/tRNA pairs and EGFP harboring stop codons TAG and TGA) for incorporating two distinct ncAAs, we generated four plasmids: 1) For EcTyr TGA +Pyl TAG , we made plasmids S13 pAcBac3-EcTyr TGA -EGFP** (EGFP** stands for EGFP-39TAG-151TGA) and pAcBac1-UbiCMbPylRS-8xtRNA CUA Pyl . 2) For EcTyr TAG +Pyl TGA , we made plasmids pAcBac3-EcTyr TAG -EGFP** and pAcBac1-CMV-MbPylRS-8xtRNA UCA Pyl .
Construction of the pAcBac3-EcTyr TAG -EGFP** was performed as previously described 1 , except only 16 tRNA copies were incorporated (instead of 20 in the original pAcBac3). The analogous pAcBac3-EcTyr TGA -EGFP** plasmid was created in a similar fashion, except only 8 tRNA copies were incorporated. To generate the pAcBac1-CMV-MbPylRS-8xtRNA UCA Pyl plasmid, a pIDT-Kan-8xtRNA UCA Pyl plasmid was first prepared containing 8 copies of tandem tRNA UCA Pyl , each driven by a U6 promoter, following a procedure reported previously 1 . The 8xtRNA cassette was excised out of this plasmid by NheI/AvrII digestion and inserted into the SpeI site of the previously reported pAcBac1-MbPylRS plasmid. An analogous cloning strategy was used to create the corresponding TAG-suppressing plasmid pAcBac1-UbiC-MbPylRS8xtRNA CUA Pyl .
For the construction of the pAcBac3-EcLeu TAG -EGFP** plasmid, DNA sequence encoding EcLeuRS-AK1 2 was PCR amplified to replace the AnapRS in the previously reported plasmid pAcBac2R-8xEcLtR-AnapRS 3 by NheI and EcoRI restriction enzyme sites. EGFP** was then PCR amplified and inserted into the SfiI sites to make the final plasmid.
EGFP** fluorescence analysis, expression and purification:
For small-scale expression analysis, HEK293T cells were seeded at a density of 600,000 cells per well for a 12-well plate the day before transfection. A total amount of 1.2 μg DNA + 4 μl PEI + 20 μl DMEM was used for transfection of each well. For the modular three-plasmid transfection, 0.4 μg of each plasmid is used. For two-plasmid transfections, 0.6 μg of each plasmid is used. Fluorescence images and EGFP expression analysis were performed 48 hours post transfection. To obtain EGFP expression data, cells were harvested and lysed as described before 1 . EGFP fluorescence in lysate was collected in a 96-well plate using a SpectraMAX M5 (Molecular Devices) (ex=480 nm and em=530 nm). Mean of three independent experiments were reported, and error bars represent standard deviation. For larger scale protein expression incorporating two ncAAs, HEK293T cells were seeded in 100 mm cell culture dishes (5 million per dish) two days before transfection. A total amount of 12 μg DNA + 50 μl PEI + 200 μl DMEM was used to transfect cells that are between 80% -90% confluency. The ncAAs were supplemented at 1 mM final concentration at the time of transfection. Cells were harvested 48 hours post-transfection, lysed with CelLytic M, and the C-terminally polyhistidine tagged protein was purified using cobalt-containing TALON metal affinity resin (Clontech) following manufacturer's protocol. Purified proteins were subjected to SDS-PAGE gels and ESI-MS (Agilent TOF HPLC-MS) for further characterization.
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Protein labeling, and MS analysis:
For click-labeling the EGFP** protein incorporating either AzF+hPrK or PrY+AzK, 1 μg of purified EGFP** was incubated with 20 μM DBCO-Cy5 (Sigma) or 50 μM Alexa Fluor 488 picolyl azide (Fisher Scientific), respectively, for 2 hours at room temperature. Identical reactions were set up with wild-type EGFP as control experiments. For labeling EGFP-39CpK-151AzF, 5 μM of protein was incubated with 50 μM DBCO-TAMRA (Click Chemistry Tools, AZ) followed by 200 μM tetrazine-fluorescein, 4 at room temperature in PBS for 30 min each. Subsequently, the reaction product was subjected to SDS-PAGE and HPLC-coupled ESI-MS analysis.
List of Primers:
EcLtR-Nhe-R: aataatGCTAGCAAAAAATACCCGGAGCGGGACTTGAACC MmPytR-Nhe-R: aataatgctagcAAAAAACGGAAACCCCGGGAATCTAACCCG EcYtR-Nhe-R: aataatGCTAGCAAAAAATGGTGGGGGAAGGATTCG BstYtR-Nhe-R: aataatGCTAGCAAAAAATGGAGGGGGACGGATTCG U6-AvrII-F: aataatCCTAGGTCGGGCAGGAAGAGGGC H1-AvrII-F: aataatCCTAGGAATTCGAACGCTGACGTCATCAACC EGFP-SfiI-F: aataatGAATTGGCCAAGGCGGCCACCATGGTG 12xHis-SfiI-R: AATTCGGCCTTAGAGGCCTTAATGATGGTGATGGTGATGATGGTGATGGTGATGATGACC LeuRS-NheI-F: aataatGGCTAGCGTTTAAACTTAAGCTTGCCGCCACCATGGAAGAGCAATACC LeuRS-EcoRI-R: attattaGAATTCTTAAACGGGCCCGCCAACGACCAGATTGAG GAAGAAAGCTCCAGGTCCCCGTGCATTATATCAAGAGTATCCCCAaAGACCATACAGGAATC  TCCTACGATTTCGAAGTCGATTTCCAGATAGTCCAGAAACTCTTTGATGAGAGCTTCAAGAT  TTTCCCGAGTACATCCCGAACCCATCTGACAGAAGTTCACCATAGTAAATTCTTCCAGGTGC  TCTTTGCCGTCAGACTCTTTCCGGTAACAAGGTCCGACTTCGAAAATTTTTATTGGGCCTGGT  AAAATCCTATCGAGTTTTCGCAGATAGTTGTAAAGAGTCGGGGCAAGCATTGGCCTCAAGCA  GAGATTTTTATCCACCCGGAAGATCTGTTTTGAAAGTTCAGTATCATTATTAATACCCATTCT  CTCCACGTATTCCGCCGGAATAAGGATAGGAGACTTTATCTCCAGAAAACCCCGGTCTACGA  AAAATTTCGTAATATCACGTTCGAGTTTACCGAGGTAGTCTTCTCTATCATTGGTATAGAGCC  GCTGAAAATCGTTTTTTCTTCTTGTCACAAGTTCAGGCTCAAGTTCCCTGAAAGGCTTTGCCA  TATTTAGAGAAATTTTATCCTCTGGACTTAAGAGAGCCTCAACCCTATCAAGCTGGCTTCTTG  TAAGTGAAGGAGCAGGAGCCGATGCGGGAACAGACGAATTTGGAGTTGATTTTGCAGGCGA  AGGTACAGATCTGGATGTGTTCGTTGATGCCTTTGCAGAAACAGAATTTTCCAGAGGCTTCG  GAGCCCTTGAAACTGATTTCGGCATAGCTTTTTTGACCTTTGGAGCAGAAACTACCCTAACTT  TCACACTGTTTTTGCTTTCGGTTGATCTTGTGAGAAAATTATTGATATCCTCGTCCGAAACCC  TACATCGTTTGCAGGTTTTTCTGTACTTATGATGTCTGAATGCTCTGGCTGTTCTACAACTCCT  GGAATTATTCACAACAAGATGGTCTCCACACGCCATTTCAATGTATATTTTACTTCTTGAGAC  CTCATGGTGCTTGATTTTGTGGAGCGTGCCAGTCCTGGACATCCAGAGCCCGGTCGCAGATA  TTAAAACATCTAATGGTTTTTTATCCATggtggcgctagccagcttgggtctccctatagtgagtcgtattaatttcgataagcca  gtaagcagtgggttctctagttagccagagagctCtagaccaagtgacgatcacagcgatccacaaacaagaaccgcgacccaaatcccggctgcga  cggaactagctgtgccacacccggcgcgtccttatataatcatcggcgttcaccgccccacggagatccctccgcagaatcgccgagaagggactactt  ttcctcgcctgttccgctctctggaaagaaaaccagtgccctagagtcacccaagtcccgtcctaaaatgtccttctgctgatactggggttctaaggccga  gtcttatgagcagcgggccgctgtcctgagcgtccgggcggaaggatcaggacgctcgctgcgcccttcgtctgacgtggcagcgctcgccgtgagg  aggggggcgcccgcgggaggcgccaaaacccggcgcggaggccttcgaacggCCActagcAAAAAACGGAAACCCCGGGA   S23   ATCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGATCTACATGATCAGGTTTCCGGGGATC  TGTGGTCTCATACAGAACTTATAAGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGATT  TCCCAGAACACATAGCGACATGCAAATATTGCAGGGCGCCACTCCCCTGTCCCTCACAGCCA  TCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGTGACACTGGGCCCGCGATTC  CTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTCCTAGCAAAAAACGGAAACCCCGGGAA  TCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGATCTACATGATCAGGTTTCCGGTGTTTCG  TCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGCATAT  GATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTCTAC  GTCACGTATTTTGTACTAATATCTTTGTGTTTACAGTCAAATTAATTCTAATTATCTCTCTAAC  AGCCTTGTATCGTATATGCAAATATGAAGGAATCATGGGAAATAGGCCCTCTTCCTGCCCGA  CctagcAAAAAACGGAAACCCCGGGAATCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGAT  CTACATGATCAGGTTTCCGGGGATCTGTGGTCTCATACAGAACTTATAAGATTCCCAAATCC  AAAGACATTTCACGTTTATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTGCAGGG  CGCCACTCCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCC  GCCTAGTGACACTGGGCCCGCGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTCC  TAGCAAAAAACGGAAACCCCGGGAATCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGAT  CTACATGATCAGGTTTCCGGTGTTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGA  AATACTTTCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCA  AACTACCCAAGAAATTATTACTTTCTACGTCACGTATTTTGTACTAATATCTTTGTGTTTACA  GTCAAATTAATTCTAATTATCTCTCTAACAGCCTTGTATCGTATATGCAAATATGAAGGAATC  ATGGGAAATAGGCCCTCTTCCTGCCCGACctagcAAAAAACGGAAACCCCGGGAATCTAACCC  GGCTGAACGGATTTAGAGTCCGTTCGATCTACATGATCAGGTTTCCGGGGATCTGTGGTCTC  ATACAGAACTTATAAGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGATTTCCCAGAA  CACATAGCGACATGCAAATATTGCAGGGCGCCACTCCCCTGTCCCTCACAGCCATCTTCCTG  CCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGTGACACTGGGCCCGCGATTCCTTGGAGC  GGGTTGATGACGTCAGCGTTCGAATTCCTAGCAAAAAACGGAAACCCCGGGAATCTAACCC  GGCTGAACGGATTTAGAGTCCGTTCGATCTACATGATCAGGTTTCCGGTGTTTCGTCCTTTCC  ACAAGATATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGCATATGATAGTC  CATTTTAAAACATAATTTTAAAACTGCAAACTACCCAAGAAATTATTACTTTCTACGTCACGT  ATTTTGTACTAATATCTTTGTGTTTACAGTCAAATTAATTCTAATTATCTCTCTAACAGCCTTG  TATCGTATATGCAAATATGAAGGAATCATGGGAAATAGGCCCTCTTCCTGCCCGACctagcAAA  AAACGGAAACCCCGGGAATCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGATCTACATG  ATCAGGTTTCCGGGGATCTGTGGTCTCATACAGAACTTATAAGATTCCCAAATCCAAAGACA  TTTCACGTTTATGGTGATTTCCCAGAACACATAGCGACATGCAAATATTGCAGGGCGCCACT  CCCCTGTCCCTCACAGCCATCTTCCTGCCAGGGCGCACGCGCGCTGGGTGTTCCCGCCTAGT  GACACTGGGCCCGCGATTCCTTGGAGCGGGTTGATGACGTCAGCGTTCGAATTCCTAGCAAA  AAACGGAAACCCCGGGAATCTAACCCGGCTGAACGGATTTAGAGTCCGTTCGATCTACATG  ATCAGGTTTCCGGTGTTTCGTCCTTTCCACAAGATATATAAAGCCAAGAAATCGAAATACTT  TCAAGTTACGGTAAGCATATGATAGTCCATTTTAAAACATAATTTTAAAACTGCAAACTACC  CAAGAAATTATTACTTTCTACGTCACGTATTTTGTACTAATATCTTTGTGTTTACAGTCAAAT 
